• Shuang-Shuang Li, Wei-Shi Zhang, Dong Ji, Ya-Lan Zhou, Hui Li, Jia-Le Yang, Yuan-Chang Xiong, Yu-Qiu Zhang, and Hua Xu.
• Department of Anesthesiology, Changhai Hospital, The Second Military Medical University, Shanghai, China.
• Neurosci. Lett. 2014 Feb 7; 560: 21-5.

AbstractDexmedetomidine, a selective alpha 2-adrenoceptor (α2AR) agonist, has provided significant analgesia in neuropathic pain. However, its underlying molecular mechanism has not been fully elucidated. In the present study, we found that intrathecal administration of dexmedetomidine alleviated mechanical allodynia induced by chronic constriction injury (CCI), and pretreatment with BRL44408 significantly reversed the dexmedetomidine-induced anti-nociceptive effect. Western blotting revealed that dexmedetomidine reduced the activation of microglia and the upregulation of interleukin-18 (IL-18) protein expression in the ipsilateral lumbar spinal dorsal horn, while BRL44408 pretreatment significantly blocked these effects of dexmedetomidine. Immunocytochemistry/immunohistochemistry indicated that the α2A-adrenoceptor was localised to microglia in primary culture, and IL-18 predominantly colocalised with the microglial marker Iba-1 in the dorsal horn of the spinal cord. These results suggest that the IL-18 signalling pathway in microglia may be involved in the anti-nociceptive effect of dexmedetomidine in rats subjected to CCI.Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

42 keywords...

hide…